Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
Characterized as a mitotic inhibitor, paclitaxel has gained importance as a promising agent for the treatment of advanced non-small cell lung cancer (NSCLC). However, whether paclitaxel has immune modulatory effects remains unclear. In this study, we analyzed 55 peripheral blood samples from NSCLC p...
Description complète
Détails bibliographiques
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 129(2008), 2 vom: 19. Nov., Seite 219-29
|
|---|
| Auteur principal: |
Zhang, Lei
(Auteur) |
|---|
| Autres auteurs: |
Dermawan, Kamtai,
Jin, Meilin,
Liu, Rongjun,
Zheng, Huiru,
Xu, Lin,
Zhang, Yi,
Cai, Yuchan,
Chu, Yiwei,
Xiong, Sidong |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | English |
|---|
| Publié: |
2008
|
|---|
| Accès à la collection: | Clinical immunology (Orlando, Fla.)
|
|---|
| Sujets: | Journal Article
Research Support, Non-U.S. Gov't
Antineoplastic Agents, Phytogenic
Interleukin-2
fas Receptor
Interferon-gamma
82115-62-6
Paclitaxel
P88XT4IS4D |
|---|